TNFSF10 and cancer: Since the death receptor agonists are often overexpressed in cancer cells 49, 50, combining the effects of TRAIL with local NP-mediated hyperthermia, by using TRAIL-functionalized iron oxide nanovectors, appears as a yet-unexplored and appealing strategy.